MDB Capital (MDBH) & Its Competitors Head-To-Head Contrast

Earnings and Valuation

This table compares MDB Capital and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MDB Capital	$5.99 million	-$6.97 million	-2.56
MDB Capital Competitors	$2.92 billion	$383.60 million	21.86

MDB Capital’s peers have higher revenue and earnings than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

MDB Capital has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500. Comparatively, MDB Capital’s peers have a beta of 5.21, suggesting that their average stock price is 421% more volatile than the S&P 500.

Institutional and Insider Ownership

0.4% of MDB Capital shares are owned by institutional investors. Comparatively, 34.3% of shares of all “Nondepository credit institutions” companies are owned by institutional investors. 55.5% of MDB Capital shares are owned by insiders. Comparatively, 22.2% of shares of all “Nondepository credit institutions” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares MDB Capital and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDB Capital	N/A	-56.19%	-48.57%
MDB Capital Competitors	-62.34%	-73.50%	-4.01%

Summary

MDB Capital peers beat MDB Capital on 6 of the 9 factors compared.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.